Lowering of serum cholesterol levels by pharmacologic intervention with statins reduces the
incidence of cardiovascular events in subjects with and without atherosclerotic …

Background: High levels of total and LDL-cholesterol are associated with an increased risk
of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

Background and Objectives HMG-CoA reductase inhibitors have been used for a decade to
lower LDL cholesterol levels and to improve cardiovascular diseases and clinical outcomes …

Background & Objectives The aim of this study was to investigate the efficacy & safety of a
new HMG-CoA reductase inhibitor, atorvastatin, to improve serum lipid profiles in patients …

Background and Purpose: There have been few reports on the efficacy and safety of statins
in the Asian population. The study objectives were to compare the efficacy and safety of …

Elevated levels of serum lipids and lipoproteins are known to play a major role in the
development of atherosclerosis and subsequent coronary heart disease (CHD). In controlled …

Data pooled from 21 atorvastatin clinical trials have been analyzed to establish the safety of
reducing low density lipoprotein cholesterol (LDL-C) levels below currently recommended …

In this 2-year study, 787 patients with hypercholesterolemia received either atorvastatin 10
mg to 80 mg/day (623 patients) or lovastatin 20 mg to 80 mg/day (164 patients). Patients …

The efficacy and safety of atorvastatin 10 mg versus simvastatin 20 mg and atorvastatin 80
mg versus simvastatin 80 mg was determined in a 6-week, prospective, randomized, open …